Specify a stock or a cryptocurrency in the search bar to get a summary
Ocumension Therapeutics
1477Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China. Address: No. 1858 Yinzhongnan Road, Suzhou, China
Analytics
WallStreet Target Price
77.22 HKDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 1477
Dividend Analytics 1477
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 1477
Stock Valuation 1477
Financials 1477
Results | 2019 | Dynamics |